ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
![Thumbnail](/bitstream/handle/1808/35115/41467_2023_Article_42061.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Issue Date
2023-10-05Author
Weidenbacher, Payton A.-B.
Sanyal, Mrinmoy
Friedland, Natalia
Tang, Shaogeng
Arunachalam, Prabhu S.
Hu, Mengyun
Kumru, Ozan S.
Kate Morris, Mary
Fontenot, Jane
Shirreff, Lisa
Do, Jonathan
Cheng, Ya-Chen
Vasudevan, Gayathri
Feinberg, Mark B.
Villinger, Francois J.
Hanson, Carl
Joshi, Sangeeta B.
Volkin, David B.
Pulendran, Bali
Kim, Peter S.
Publisher
Nature Research
Type
Article
Article Version
Scholarly/refereed, publisher version
Rights
Copyright © The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Metadata
Show full item recordAbstract
While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants.
Collections
Citation
Weidenbacher PA, Sanyal M, Friedland N, Tang S, Arunachalam PS, Hu M, Kumru OS, Morris MK, Fontenot J, Shirreff L, Do J, Cheng YC, Vasudevan G, Feinberg MB, Villinger FJ, Hanson C, Joshi SB, Volkin DB, Pulendran B, Kim PS. Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat Commun. 2023 Oct 5;14(1):6211. doi: 10.1038/s41467-023-42061-4. Erratum for: Nat Commun. 2023 Apr 17;14(1):2149. doi: 10.1038/s41467-023-37417-9. PMID: 37798288; PMCID: PMC10556009
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.